Login to Your Account

ERS Roundup

Tuesday, September 27, 2011
Mundipharma International Ltd., of Cambridge, UK, said new data from three Phase III studies showed that flutiform, a combination of fluticasone propionate, an inhaled corticosteroid and long-acting beta2-agonist formoterol fumarate improved lung function and effectively controlled symptoms across different asthma severities in adolescents and adults.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription